FDA clears IND for Cerveau ’ s tau imaging agent
Cerveau Technologies said today that the FDA cleared the investigational new drug application for its tau imaging agent.
The company plans to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess neurofibrillary tangles in the brain. NFTs composed of aggregated tau protein are characteristic of certain neurodegenerative conditions like Alzheimer’s disease.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA clears IND for Cerveau’s tau imaging agent appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diagnostics Food & Drug Administration (FDA) Neurological Regulatory/Compliance Cerveau Technologies Source Type: news
More News: Brain | Clinical Trials | Investigational New Drugs | Neurology | New Drug Applications | PET Scan